Regeneron's blockbuster eye drug posts weaker sales due to inventory impact
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St slips as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia releases AI safety software it says could have stopped Hugging Face hack
Regeneron Pharma (REGN) PT Lowered to $1,185 at RBC Capital
May 3, 2024 6:46 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,185.00 (from $1,189.00) while maintaining a Outperform rating.
The analyst comments "Overall, a reasonably solid quarter, with Eylea HD looking good, Eylea 2mg missing probably to a... More
Regeneron (REGN) misses earnings, revenue expectations
May 2, 2024 7:05 AM EDTRegeneron (NASDAQ: REGN) experienced a slight decline in its stock price, falling 1.82% after reporting first-quarter earnings and revenue that fell short of Wall Street expectations. The biotechnology company announced an adjusted EPS of $9.55, which was below the analyst estimate of $10.19. Revenue for the quarter was $3.15 billion, also missing the consensus estimate of $3.22 billion.
Despite the overall revenue decrease of 1% from the same quarter last year, the company highlighted a 7% increase when excluding sales from Ronapreve, a COVID-19 treatment. Notably,... More
